3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Melanoma
7
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Rectal Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Neoplasm, Residual
2
Hyperthermia
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Pneumonitis
1
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled